Medical Device Recall Improvement Act of 2025

Bill Number

S. 3421

Origin Chamber

Senate

Congress

119th Congress, Session 1

Status

Introduced

Latest Action

2025-12-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S8625)

Last Updated

2026-01-06T06:24:16Z

AI-Generated Summary

Purpose

The Medical Device Recall Improvement Act of 2025 aims to enhance the safety and efficiency of medical device recalls by requiring electronic notifications to the U.S. Food and Drug Administration (FDA), device users, health professionals, and certain patients. It seeks to standardize and speed up recall communications to better protect public health from faulty devices.

Key Provisions

• Electronic Notification Format (Section 518B):
• The FDA must create and publish an electronic template for recall notifications within 2 years of the bill's enactment.
• This template must include mandatory details such as the manufacturer's name and contact information, the reason for the recall (e.g., correction or market removal), device specifics including its unique device identifier (UDI, a code that tracks devices like serial numbers), and tailored information for device user facilities (e.g., hospitals), health professionals, and patients about risks and mitigation steps.
• Optional elements can be added as needed by the FDA.
• Manufacturers or importers must submit recall notices to the FDA electronically starting 180 days after the template is established.
• The FDA must review submissions within 2 business days and provide feedback within 3 business days on what information should be shared with facilities and professionals.
• Manufacturers must then notify facilities and professionals electronically after the FDA's initial review, with additional notices as needed.
• The FDA will maintain a public, downloadable online database of recall information.

• Patient Notification (Section 518C):
• Recall plans must include notifying patients treated with the affected device outside of facilities (e.g., at home or in clinics).
• Notices to facilities and professionals must detail patient-specific risks and instruct them to inform affected patients.
• This applies to Class I or Class II recalls (serious or moderate risk levels) for Class II or Class III devices (moderate to high-risk devices) that are implanted, life-sustaining/supporting, or commonly used in children.
• Facilities and professionals are not required to share patient details with manufacturers.

• Enforcement and Funding:
• Failure to submit electronic notifications or provide patient notices becomes a prohibited act under the Federal Food, Drug, and Cosmetic Act (FD&C Act), potentially leading to penalties like fines or seizures.
• Authorizes $6.7 million for fiscal year 2026, $1.7 million for 2027, and $1 million annually for 2028–2030 to support implementation, including hiring staff.

Significant Changes to Existing Law

• Amends the FD&C Act by adding new sections (518B and 518C) after existing recall provisions, shifting from potentially paper-based or varied formats to a mandatory electronic system.
• Introduces required patient notifications for specific high-risk devices, which were not explicitly mandated before.
• Adds two new prohibited acts (sections 301(jjj) and 301(kkk)) for non-compliance with electronic submissions and patient notices, strengthening enforcement.
• Creates a public database for recalls, increasing transparency beyond current FDA reporting.

Potential Impacts

• Government Agencies: The FDA gains streamlined electronic tools for faster reviews and a public database, potentially reducing administrative burdens but requiring initial setup costs and new personnel. This could improve recall oversight and response times.
• Citizens: Patients, especially those with implanted or life-critical devices, benefit from clearer risk information and actions to take, potentially reducing harm from faulty devices. Health professionals and facilities get standardized, quicker alerts, aiding safer patient care.
• International Relations: Minimal direct impact, though U.S. manufacturers with global operations may need to align electronic systems with international standards, indirectly affecting trade in medical devices.

Main Stakeholders Affected

• Medical Device Manufacturers and Importers: Must adopt electronic reporting, provide detailed notifications, and ensure patient risk communications, increasing compliance costs but standardizing processes.
• FDA: Responsible for developing the system, reviewing submissions, maintaining the database, and enforcing rules.
• Device User Facilities (e.g., hospitals, nursing homes) and Health Professionals (e.g., doctors, nurses): Receive electronic alerts and are tasked with notifying patients, potentially adding workload but improving safety protocols.
• Patients: Particularly those using high-risk devices outside facilities, who gain direct access to recall risks and remedies via professionals or the public database.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens FDA authority over recalls without altering core device classification (Class I–III based on risk). Prohibited acts align with existing FD&C Act penalties, ensuring enforceability through civil or criminal measures. The patient notification rule respects privacy by not requiring disclosure of patient data to manufacturers.
• Constitutional: No apparent conflicts; it advances public health under Congress's commerce clause powers without infringing on free speech or due process, as requirements are procedural and tied to regulated products.
• Political: Promotes bipartisanship on health safety by addressing recall inefficiencies (e.g., past delays in notifying users). Could face industry pushback on costs but gains support from consumer advocates; funding authorization signals commitment without mandating spending, leaving room for budget debates.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Durbin, Richard J. [D-IL]

Recent Actions

• 2025-12-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S8625)
• 2025-12-10: Introduced in Senate

Bill Versions

• Medical Device Recall Improvement Act of 2025 — issued 2025-12-10 — PDF (7 pages)